Asunercept

N/A

Report date: 2024/07/01 14:21:41

Base Information

Drug NameAsunercept
Drug Alias NameApoceptAsinerceptCD95 Ligand Fas Ligand Inhibitor (Apogenix)CAN-008APG-101
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionSoluble Fas ligand inhibitors
TargetsSoluble Fas ligand
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursSkin Diseases +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanPolandRussian Federation +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesApogenix Gmbh
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesApogenix GmbhCanbridge Life Sciences LtdCANbridge (Shanghai) Life Sciences Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursSkin Diseases +[6] 
Inactive IndicationsMyelodysplastic Syndromes

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank